HSBC WAR. CALL 06/25 BAYN/ DE000HG2TSU0 /
7/31/2024 9:36:18 PM | Chg.-0.0010 | Bid9:58:23 PM | Ask9:58:23 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.0040EUR | -20.00% | 0.0010 Bid Size: 20,000 |
0.0170 Ask Size: 20,000 |
BAYER AG NA O.N. | 92.00 - | 6/18/2025 | Call |
GlobeNewswire
5/30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
5/30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
2/13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
1/5
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)